MPR Weekly Dose Podcast

MPR Weekly Dose Podcast Episode 93

The FDA weigh up mandatory education for opioid prescribers; There’s an increase in the sale of strong psychoactive THC products; Brukinsa and Exkivity gain approval, respectively; And a number of supplement companies received FDA warning letters.

MPR Weekly Dose Podcast Episode 92

This week we have news on pediatric influenza vaccine guidance; Moderna submit data for their COVID-19 booster dose; There’s new FDA warnings for some JAK inhibitors; Trudhesa nasal spray is approved; And the FDA places a clinical hold on a gene therapy for phenylketonuria.

MPR Weekly Dose Podcast Episode 91

The first COVID-19 vaccine is fully approved by the FDA, we’ll go into all that that entails and also news regarding booster doses, off-label recommendations, promising antibody treatments and a BLA submission from Moderna for their mRNA vaccine.

MPR Weekly Dose Podcast Episode 90

This week we have significant news on the status of a third COVID-19 vaccine booster dose, as well as news for an encephalitis vaccine, another Jardiance indication, an FDA warning concerning patient wristbands, and Jemperli gets accelerated approval. 

MPR Weekly Dose Podcast Episode 89

Big news on the COVID-19 vaccine booster dose. The CDC issues new recommendations on vaccines. What protection the Moderna vaccine offers after 6 months. A treatment approved for Pompe disease. And the FDA denies an application for a new roxadustat indication.

MPR Weekly Dose Podcast Episode 88

The FDA authorizes a postexposure prophylaxis for COVID-19; A new treatment is okay’d for lupus; A higher dose naloxone nasal spray became available; The risk evaluation and mitigation program for Clozapine has had important changes, and finally, Istodax has had an indication withdrawn.

MPR Weekly Dose Podcast Episode 86

This week on the pod we speak about a fact sheet update for the Janssen COVID vaccine. Pfizer and BioNTech are working on a booster version of their vaccine. A supplement is found to contain a prescription ingredient. There’s a new treatment for patients with diabetic kidney disease. And two sunscreen brands are recalled due to the presence of benzene.

MPR Weekly Dose Podcast Episode 85

This week Pfizer recalled their smoking cessation therapy Chantix. A treatment for acute bacterial skin and skin structure infections becomes available. Aduhelm, the newly approved Alzheimer Disease treatment, has its label updated. A blood lead level test is recalled, and there’s updates to the cancer drug Keytruda.

MPR Weekly Dose Podcast 84

The FDA grants Emergency Use to Actemra to treat hospitalized COVID patients. Revisions are been made to the fact sheets for the Moderna and Pfizer BioNTech COVID vaccines to include information related to the risk of myocarditis and pericarditis. A new treatment is approved for some cancer patients allergic to E. coli-Derived asparaginase products. Meanwhile,…

MPR Weekly Dose Podcast 83

This week the FDA approved a first-in-class switch for an antihistamine nasal spray, a new oral contraceptive, and Pradaxa was approved to prevent venous thromboembolism in pediatric patients. Also, we look at a published report on the real-world efficacy of the COVID-19 treatment remdesivir. 

MPR Weekly Dose Podcast 82

This week the FDA approved a regenerative skin tissue therapy and a treatment for advanced mastocytosis, while Novavax’s vaccine for COVID and a novel treatment for MDD show promise, also the FDA issue warning concering hand sanitizers.

MPR Weekly Dose Podcast 81

This week’s episode covers the aducanumab approval. There’s also approvals in treatments for obesity and a first treatment for Plasminogen Deficiency Type 1. Plus, Moderna have sent an EUA request to extend use of their COVID-19 vaccine to those aged 12 and older.

MPR Weekly Dose Podcast 79

This week we have news of changes to the storage of the Pfizer-BioNTech vaccine; A gene therapy gets Fast Track status by the FDA; Vitiligo cream shows promise in clinical trials; And outcomes in atherosclerotic cardiovascular disease are compared for different aspirin dosages.

MPR Weekly Dose Podcast 78

This week we have news of a COVID-19 vaccine authorization expansion for adolescents; A new postoperative pain treatment; There’s a new insulin smart pen devices; Insulin products are recalled; And the FDA grants fast track status to a potential treatment for the rare disease, FSHD.

MPR Weekly Dose Podcast 77

New guidelines on mask use; J&J vaccine update; Novel major depressive disorder treatment gains Priority Review; A scabies topical suspension; And a device to help stroke rehabilitation. 

MPR Weekly Dose Podcast 76

In this week’s pod, the FDA review the Emergency Use Authorization for bamlanivimab; Issues are identified at a Janssen manufacturing facility; Merck halts trials for investigational COVID therapy; A novel contraceptive is approved; And Ragwitek has its approval expanded.

MPR Weekly Dose Podcast 75

The latest status on the Janssen vaccine; Updated guidance from the National Institutes of Health on COVID-19 antibody treatment; The FDA changes in-person mifepristone dispensing; A prefilled-syringe for Xolair injection is approved; And the AI world comes to colonoscopies.

MPR Weekly Dose Podcast 74

Back to regular programming this week with a summary of the top news, which includes updated travel guidance; Six month efficacy data for the Moderna and Pfizer-BioNTech vaccines; Vial doses increased for Moderna; A new ADHD drug is approved; And the FDA has issued a safety communication regarding lamotrigine.

MPR Weekly Dose #73: Interview with Dr Joshua Barocas

To get a better understanding of the situation and how the future months could unfold, MPR sat down with Joshua Barocas, MD, an Assistant Professor of Medicine at the Boston University School of Medicine and Infectious Diseases physician at Boston Medical Center.

MPR Weekly Dose Podcast 72

This week we have new study data on the real-world effectiveness of the Pfizer-BioNTech vaccine; The number of Americans who are completing both vaccine doses; A vaccine trial that has started in children; Approval in acute bacterial skin and skin structure infections; And results from the tocilizumab-remdesivir combo trial.